OBJECTIVES: The susceptibility of clinical isolates of Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), to host-derived cationic antimicrobial peptides was investigated. METHODS: We examined the susceptibility of 190 clinical strains of methicillin-susceptible S. aureus (MSSA) and 304 strains of MRSA to two different classes of cationic antimicrobial peptides: LL-37 and human beta-defensin-3 (hBD3). Out of the total 494 clinical strains, a random selection of 54 S. aureus strains was examined to establish the relationship between the net charge, or zeta potential, of each strain and its susceptibility to hBD3 or LL-37. To further confirm bacterial susceptibility to either hBD3 or LL-37, we concurrently measured: (i) percentage survival after in vitro bacterial exposure and (ii) MBCs for both MRSA and MSSA strains. RESULTS: Of the 54 randomly selected S. aureus strains, those MRSA strains resistant to LL-37 showed significantly higher zeta potentials than those susceptible to LL-37 (P < 0.05). In contrast, there was no difference in bacterial zeta potentials for MRSA strains that showed either resistance or susceptibility to hBD3. In addition, resistance to LL-37, but not to hBD3, as determined by either percentage survival or MBC, was significantly elevated in highly methicillin-resistant strains of S. aureus when compared with MSSA strains (P < 0.01). CONCLUSIONS: Clinical strains of MRSA, but not MSSA, that demonstrated an increased net charge also showed elevated resistance to LL-37, but not to hBD3.
OBJECTIVES: The susceptibility of clinical isolates of Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), to host-derived cationic antimicrobial peptides was investigated. METHODS: We examined the susceptibility of 190 clinical strains of methicillin-susceptible S. aureus (MSSA) and 304 strains of MRSA to two different classes of cationic antimicrobial peptides: LL-37 and humanbeta-defensin-3 (hBD3). Out of the total 494 clinical strains, a random selection of 54 S. aureus strains was examined to establish the relationship between the net charge, or zeta potential, of each strain and its susceptibility to hBD3 or LL-37. To further confirm bacterial susceptibility to either hBD3 or LL-37, we concurrently measured: (i) percentage survival after in vitro bacterial exposure and (ii) MBCs for both MRSA and MSSA strains. RESULTS: Of the 54 randomly selected S. aureus strains, those MRSA strains resistant to LL-37 showed significantly higher zeta potentials than those susceptible to LL-37 (P < 0.05). In contrast, there was no difference in bacterial zeta potentials for MRSA strains that showed either resistance or susceptibility to hBD3. In addition, resistance to LL-37, but not to hBD3, as determined by either percentage survival or MBC, was significantly elevated in highly methicillin-resistant strains of S. aureus when compared with MSSA strains (P < 0.01). CONCLUSIONS: Clinical strains of MRSA, but not MSSA, that demonstrated an increased net charge also showed elevated resistance to LL-37, but not to hBD3.
Authors: P K Singh; H P Jia; K Wiles; J Hesselberth; L Liu; B A Conway; E P Greenberg; E V Valore; M J Welsh; T Ganz; B F Tack; P B McCray Journal: Proc Natl Acad Sci U S A Date: 1998-12-08 Impact factor: 11.205
Authors: Mark W Lisanby; Melissa K Swiecki; Brian L P Dizon; Kathryn J Pflughoeft; Theresa M Koehler; John F Kearney Journal: J Immunol Date: 2008-10-01 Impact factor: 5.422
Authors: Rachel L Soon; Roger L Nation; Stewart Cockram; Jennifer H Moffatt; Marina Harper; Ben Adler; John D Boyce; Ian Larson; Jian Li Journal: J Antimicrob Chemother Date: 2010-11-16 Impact factor: 5.790
Authors: Nina M van Sorge; Federico C Beasley; Ivan Gusarov; David J Gonzalez; Maren von Köckritz-Blickwede; Sabina Anik; Andrew W Borkowski; Pieter C Dorrestein; Evgeny Nudler; Victor Nizet Journal: J Biol Chem Date: 2013-01-15 Impact factor: 5.157
Authors: George Sakoulas; Cheryl Y Okumura; Wdee Thienphrapa; Joshua Olson; Poochit Nonejuie; Quang Dam; Abhay Dhand; Joseph Pogliano; Michael R Yeaman; Mary E Hensler; Arnold S Bayer; Victor Nizet Journal: J Mol Med (Berl) Date: 2013-12-03 Impact factor: 4.599
Authors: Katarzyna Leszczynska; Dorota Namiot; Fitzroy J Byfield; Katrina Cruz; Malgorzata Zendzian-Piotrowska; David E Fein; Paul B Savage; Scott Diamond; Christopher A McCulloch; Paul A Janmey; Robert Bucki Journal: J Antimicrob Chemother Date: 2012-11-07 Impact factor: 5.790